Análisis de los contenidos de historia en el ámbito educativo

En nuestro trabajo "Análisis de los contenidos de Historia en el ámbito educativo´´ hemos querido investigar la importancia de la asignatura dentro de la Educación Primaria y analizar los contenidos que la conforman. Dentro de la investigación hemos entrevistado a alumnos, docentes y futuros docentes para conocer su opinión sobre la misma, qué esperan de la asignatura y cuál creen que es la metodología correcta para impartirla y que sea motivante para ambos agentes educativos, también hemos analizado el papel que ha jugado la asignatura a lo largo de la historia de la educación en España y el papel que juega actualmente según los documentos oficiales, se podrá encontrar también análisis del material usado actualmente para impartir las clases, siendo estos libros de texto ya que es el material que usan los docentes que han sido entrevistados como base para sus sesiones, por ultimo podrán encontrar una propuesta didáctica que creemos motivante para los alumnos y con la que pueden aprender los contenidos que se exigen de una manera más interactiva y jugando ellos y ellas el papel protagonista en las clases.In our work "Analysis of the contents of History in the educational field '' we wanted to investigate the importance of the subject in Primary Education and analyze the contents that comprise it. Within the research we interviewed students, teachers and future teachers to know their opinion about it, what they expect from the subject and what they believe is the correct methodology to teach and that is motivating for both educational agents, we have also analyzed the role who has played the subject throughout the history of education in Spain and the role that currently plays according to official documents, you can also find analysis of the material currently used to teach the classes, these textbooks being that it is the material used by the teachers who have been interviewed as a basis for their sessions, finally they can find a didactic proposal that we believe motivating for the students and with which they can learn the contents that are required in a more interactive way and playing them and they protagonist role in the classes and playing, they will be the real protagonist in their classes.Universidad de Sevilla. Grado en Educación Primari

Resultados de la Vigilancia Epidemiológica de las enfermedades transmisibles. Informe anual. Año 2015

El objetivo final de la vigilancia de las enfermedades transmisibles es reducir su incidencia en la comunidad. La Red Nacional de Vigilancia Epidemiológica (RENAVE) tiene entre sus funciones la recogida sistemática de la información epidemiológica, su análisis e interpretación y la difusión de los resultados. Este informe presenta los resultados de la vigilancia de las enfermedades transmisibles para el año 2015 realizada por los servicios de vigilancia de las comunidades autónomas y el Centro Nacional de Epidemiología (CNE) de acuerdo a los protocolos de la RENAVE.N

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Infected pancreatic necrosis: outcomes and clinical predictors of mortality. A post hoc analysis of the MANCTRA-1 international study

: The identification of high-risk patients in the early stages of infected pancreatic necrosis (IPN) is critical, because it could help the clinicians to adopt more effective management strategies. We conducted a post hoc analysis of the MANCTRA-1 international study to assess the association between clinical risk factors and mortality among adult patients with IPN. Univariable and multivariable logistic regression models were used to identify prognostic factors of mortality. We identified 247 consecutive patients with IPN hospitalised between January 2019 and December 2020. History of uncontrolled arterial hypertension (p = 0.032; 95% CI 1.135-15.882; aOR 4.245), qSOFA (p = 0.005; 95% CI 1.359-5.879; aOR 2.828), renal failure (p = 0.022; 95% CI 1.138-5.442; aOR 2.489), and haemodynamic failure (p = 0.018; 95% CI 1.184-5.978; aOR 2.661), were identified as independent predictors of mortality in IPN patients. Cholangitis (p = 0.003; 95% CI 1.598-9.930; aOR 3.983), abdominal compartment syndrome (p = 0.032; 95% CI 1.090-6.967; aOR 2.735), and gastrointestinal/intra-abdominal bleeding (p = 0.009; 95% CI 1.286-5.712; aOR 2.710) were independently associated with the risk of mortality. Upfront open surgical necrosectomy was strongly associated with the risk of mortality (p < 0.001; 95% CI 1.912-7.442; aOR 3.772), whereas endoscopic drainage of pancreatic necrosis (p = 0.018; 95% CI 0.138-0.834; aOR 0.339) and enteral nutrition (p = 0.003; 95% CI 0.143-0.716; aOR 0.320) were found as protective factors. Organ failure, acute cholangitis, and upfront open surgical necrosectomy were the most significant predictors of mortality. Our study confirmed that, even in a subgroup of particularly ill patients such as those with IPN, upfront open surgery should be avoided as much as possible. Study protocol registered in ClinicalTrials.Gov (I.D. Number NCT04747990)

Measurement of the ratios of branching fractions R(D∗)\mathcal{R}(D^{*}) and R(D0)\mathcal{R}(D^{0})

The ratios of branching fractions $\mathcal{R}(D^{*})\equiv\mathcal{B}(\bar{B}\to D^{*}\tau^{-}\bar{\nu}_{\tau})/\mathcal{B}(\bar{B}\to D^{*}\mu^{-}\bar{\nu}_{\mu})$ and $\mathcal{R}(D^{0})\equiv\mathcal{B}(B^{-}\to D^{0}\tau^{-}\bar{\nu}_{\tau})/\mathcal{B}(B^{-}\to D^{0}\mu^{-}\bar{\nu}_{\mu})$ are measured, assuming isospin symmetry, using a sample of proton-proton collision data corresponding to 3.0 fb${ }^{-1}$ of integrated luminosity recorded by the LHCb experiment during 2011 and 2012. The tau lepton is identified in the decay mode $\tau^{-}\to\mu^{-}\nu_{\tau}\bar{\nu}_{\mu}$. The measured values are $\mathcal{R}(D^{*})=0.281\pm0.018\pm0.024$ and $\mathcal{R}(D^{0})=0.441\pm0.060\pm0.066$, where the first uncertainty is statistical and the second is systematic. The correlation between these measurements is $\rho=-0.43$. Results are consistent with the current average of these quantities and are at a combined 1.9 standard deviations from the predictions based on lepton flavor universality in the Standard Model.Comment: All figures and tables, along with any supplementary material and additional information, are available at https://cern.ch/lhcbproject/Publications/p/LHCb-PAPER-2022-039.html (LHCb public pages

Resultados de la Vigilancia Epidemiológica de las enfermedades transmisibles. Informe anual. 2017-2018

El objetivo final de la vigilancia de las enfermedades transmisibles es reducir su incidencia en la comunidad. La Red Nacional de Vigilancia Epidemiológica (RENAVE) tiene entre sus funciones la recogida sistemática de la información epidemiológica, su análisis e interpretación y la difusión de los resultados1. Este informe presenta los resultados de la vigilancia de las enfermedades transmisibles para los años 2017 y 2018 realizada por los servicios de vigilancia de las comunidades autónomas (CCAA). El Centro de Coordinación de Alertas y Emergencias (CCAES) del Ministerio de Sanidad coordina a las CCAA para llevar a cabo esta actividad y la gestión de la información la realiza el Centro Nacional de Epidemiología del Instituto de Salud Carlos III de acuerdo a los protocolos de la RENAVE.Agradecimientos Abreviatruras y Acrónimos usados en este informe. 1. Introducción 2. Vigilancia de las enfermedades infecciosas en 2017-2018. 3. Enfermedades transmitidas por alimentos y agua 4. Enfermedades prevenibles por la vacunación.5. Enfermedades de transmisión respiratoria 6. Enfermedades transmitidas por vectores 7. Zoonosis 8. Enfermedades de transmisión sexual y parenteral 9. Encefalopatías espongiformes transmisibles humanas. 10. AnexosN

Resultados de la Vigilancia Epidemiológica de las enfermedades transmisibles. Informe anual. Año 2016

El objetivo final de la vigilancia de las enfermedades transmisibles es reducir su incidencia en la comunidad. La Red Nacional de Vigilancia Epidemiológica (RENAVE) tiene entre sus funciones la recogida sistemática de la información epidemiológica, su análisis e interpretación y la difusión de los resultados. Este informe presenta los resultados de la vigilancia de las enfermedades transmisibles para el año 2016 realizada por los servicios de vigilancia de las comunidades autónomas y el Centro Nacional de Epidemiología (CNE) de acuerdo a los protocolos de la RENAVEAgradecimientos Abreviatruras y Acrónimos usados en este informe. 1. Introducción 2. Vigilancia de las enfermedades infecciosas en 2016. Fuentes de datos y sistemas de notificación de las enfermedades Métodos, presentación e interpretación de la información Calidad de los datos y limitaciones 3. Enfermedades transmitidas por alimentos y agua. Botulismo. Campilobacteriosis. Cólera Criptosporidiosis. Infección por E. coli productor de toxina shiga o verotoxina. Fiebre tifoidea y paratifoidea. Giardiasis. Hepatitis A. Listeriosis. Salmonelosis. Shigelosis. Triquinosis. Yersiniosis. 4. Enfermedades prevenibles por la vacunación. Difteria. Enfermedad meningocócica Temporada 2015-2016. Enfermedad neumocócica invasora. Enfermedad invasora por Haemophilus influenzae. Parotiditis. Rubéola y Síndrome de Rubéola Congénita. Sarampión. Tétanos y Tétanos Neonatal. Tos ferina. Varicela 5. Enfermedades de transmisión aérea. Gripe. Legionelosis. Lepra. Tuberculosis. 6. Enfermedades transmitidas por vectores. Dengue. Fiebre exantemática mediterránea. Fiebre exantemática mediterránea. Fiebre exantemática mediterránea. Fiebre Hemorrágica de Crimea-Congo. Fiebre del Nilo Occidental. Fiebre Recurrente. Transmitida por garrapatas. Leishmaniasis. Paludismo. Enfermedad por virus Chikungunya. Enfermedad por virus Zika. 7. Zoonosis. Brucelosis. Carbunco. Hidatidosis. Fiebre Q. Tularemia. 8. Enfermedades de transmisión sexual y parenteral. Hepatitis B. Hepatitis C. Infección Gonocócica. Infección por Chlamydia trachomatis (excluye linfogranuloma venéreo). Infección por el VIH y SIDA. Linfogranuloma venéreo. Sífilis. Sífilis Congénita.S

Study of b−b-hadron decays to Λc+h−h′−\Lambda_c^+h^-h^{\prime -} final states

Decays of $\Xi_{b}^{-}$ and $\Omega_{b}^{-}$ baryons to $\Lambda_{c}^{+} h^- h^{\prime -}$ final states, with $h^- h^{\prime -}$ being $\pi^{-}\pi^{-}$, $K^{-}\pi^{-}$ and $K^{-}K^{-}$ meson pairs, are searched for using data collected with the LHCb detector. The data sample studied corresponds to an integrated luminosity of $8.7 \rm fb^{-1}$ of $pp$ collisions collected at centre-of-mass energies $\sqrt{s} = 7$, $8$ and $13 \rm TeV$. The products of the relative branching fractions and fragmentation fractions for each signal mode, relative to the $B^{-} \rightarrow \Lambda_{c}^{+} \bar{p} \pi^{-}$ mode, are measured, with $\Xi_{b}^{-} \rightarrow\Lambda_{c}^{+} K^{-} \pi^{-}$, $\Xi_{b}^{-} \rightarrow\Lambda_{c}^{+} K^{-} K^{-}$ and $\Omega_{b}^{-} \rightarrow\Lambda_{c}^{+} K^{-} K^{-}$ decays being observed at over $5\,\sigma$ significance. The $\Xi_{b}^{-} \rightarrow\Lambda_{c}^{+} K^{-} \pi^{-}$ mode is also used to measure the $\Xi_{b}^{-}$ production asymmetry, which is found to be consistent with zero. In addition, the $B^{-} \rightarrow \Lambda_{c}^{+} \bar{p} K^{-}$ decay is observed for the first time, and its branching fraction is measured relative to that of the $B^{-} \rightarrow \Lambda_{c}^{+} \bar{p} \pi^{-}$ mode.Decays of $\Xi_b^-$ and $\Omega_b^-$ baryons to $\Lambda_c^+ h^- h^{\prime -}$ final states, with $h^- h^{\prime -}$ being $\pi^-\pi^-$, $K^-\pi^-$ and $K^-K^-$ meson pairs, are searched for using data collected with the LHCb detector. The data sample studied corresponds to an integrated luminosity of $8.7\,\mathrm{fb}^{-1}$ of $pp$ collisions collected at centre-of-mass energies $\sqrt{s} = 7$, $8$ and $13\,\mathrm{Te\kern -0.1em V}$. The products of the relative branching fractions and fragmentation fractions for each signal mode, relative to the $B^- \to \Lambda_c^+ \overline{p} \pi^-$ mode, are measured, with $\Xi_{b}^- \to\Lambda_{c}^+ K^- \pi^-$, $\Xi_{b}^- \to\Lambda_{c}^+ K^- K^-$ and $\Omega_{b}^- \to\Lambda_{c}^+ K^- K^-$ decays being observed at over $5\,\sigma$ significance. The $\Xi_{b}^- \to\Lambda_{c}^+ K^- \pi^-$ mode is also used to measure the $\Xi_{b}^-$ production asymmetry, which is found to be consistent with zero. In addition, the $B^- \to \Lambda_{c}^+ \overline{p} K^-$ decay is observed for the first time, and its branching fraction is measured relative to that of the $B^- \to \Lambda_{c}^+ \overline{p} \pi^-$ mode

Search for the Bs0→μ+μ−γB_s^0 \rightarrow \mu^+\mu^-\gamma decay

International audienceA search for the fully reconstructed $B_s^0 \rightarrow \mu^+\mu^-\gamma$ decay is performed at the LHCb experiment using proton-proton collisions at $\sqrt{s}=13$ TeV corresponding to an integrated luminosity of $5.4\,\mathrm{fb^{-1}}$. No significant signal is found and upper limits on the branching fraction in intervals of the dimuon mass are set \begin{align} {\cal B}(B_s^0 \rightarrow \mu^+\mu^-\gamma) < 4.2\times10^{-8},~&m(\mu\mu)\in[2m_\mu,~1.70]\,\mathrm{GeV/c^2} ,\nonumber {\cal B}(B_s^0 \rightarrow \mu^+\mu^-\gamma) < 7.7\times10^{-8},~&m(\mu\mu)\in[1.70,~2.88]\,\mathrm{GeV/c^2},\nonumber {\cal B}(B_s^0 \rightarrow \mu^+\mu^-\gamma) < 4.2\times10^{-8},~&m(\mu\mu)\in[3.92 ,~m_{B_s^0}]\,\mathrm{GeV/c^2},\nonumber \end{align} at 95% confidence level. Additionally, upper limits are set on the branching fraction in the $[2m_\mu,~1.70]\,\mathrm{GeV/c^2}$ dimuon mass region excluding the contribution from the intermediate $\phi(1020)$ meson, and in the region combining all dimuon-mass intervals